staging-island.nuplazidhcp.com Open in urlscan Pro
2606:4700::6812:11ab  Public Scan

Form analysis
0 forms found in the DOM

Text Content

×

Welcome to the NUPLAZID® (pimavanserin) website. This information is intended
for US healthcare professionals only.


I am a healthcare provider

I am a patient/caregiver
   
 * Full Prescribing Information
 * Important Safety Information
 * Patient/Caregiver Site
   
 * Order Samples
 * Contact a Rep


 * About PD Psychosis
 * About NUPLAZID
   * Efficacy
   * Safety & Tolerability
   * Dosing
   * Proposed MOA
 * Real-World Evidence
   
 * Expert Perspectives
 * Enroll in Acadia Connect ®
 * Resources
 * Important Safety Information
 * Patient/Caregiver Site
 * Order Samples

Download the Treatment
and Service Request Form

From when you first discuss Parkinson’s disease (PD) psychosis, to how you
choose to treat it—

EVERY MOVE MATTERS

Choose NUPLAZID® (pimavanserin)—first and only FDA-approved treatment for
hallucinations and delusions associated with PD-psychosis.

X



From early signs to clinical diagnosis

Experts explore the onset of PD-related hallucinations and delusions, its
clinical implications, and the steps taken to treat patients.

See more expert perspectives


SYMPTOMS OF PD PSYCHOSIS CAN GET WORSE OVER TIME1,2

 * Hallucinations with insight can progress to hallucinations without insight
   and delusions
 * Because patients commonly do not disclose their nonmotor symptoms, screening
   early for hallucinations and delusions may help identify psychosis earlier



See how symptoms impact daily life



NUPLAZID SIGNIFICANTLY REDUCED THE FREQUENCY AND/OR SEVERITY OF HALLUCINATIONS
AND DELUSIONS ASSOCIATED WITH PD PSYCHOSIS WITHOUT IMPACTING MOTOR FUNCTION3,4

 * Primary efficacy was evaluated based on change from baseline to Week 6 in
   SAPS-PD total score (n=95 NUPLAZID; n=90)
 * A key secondary endpoint was motor function change from baseline to Week 6 in
   UPDRS Parts II+III



SAPS-PD=Scale for the Assessment of Positive Symptoms adapted for Parkinson’s
disease; UPDRS Parts II+III=Unified Parkinson’s Disease Rating Scale Parts II
and III.

Learn about the proven efficacy of NUPLAZID




NUPLAZID HAS A DEMONSTRATED SAFETY PROFILE IN PATIENTS WITH PD PSYCHOSIS3,5

 * The adverse reactions (≥2% for NUPLAZID and greater than placebo) were
   peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%),
   hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2%
   vs <1%)
 * Selected nonmotor adverse reactions included sedation-related events (6.4%
   NUPLAZID vs 5.2% placebo) and orthostatic hypotension–related events (6.9%
   NUPLAZID vs 10.4% placebo)
   * Sedation-related events included sedation, somnolence, fatigue, asthenia,
     lethargy, and hypersomnia
   * Orthostatic hypotension–related events included dizziness, hypotension,
     orthostatic hypotension, orthostatic intolerance, syncope, vertigo
     positional, postural orthostatic tachycardia syndrome, and vertigo.






IMPORTANT SAFETY INFORMATION



WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

 * Elderly patients with dementia-related psychosis treated with antipsychotic
   drugs are at an increased risk of death.

 * NUPLAZID is not approved for the treatment of patients with dementia who
   experience psychosis unless their hallucinations and delusions are related to
   Parkinson’s disease.

Contraindication: NUPLAZID is contraindicated in patients with a history of a
hypersensitivity reaction to pimavanserin or any of its components. Rash,
urticaria, and reactions consistent with angioedema (e.g., tongue swelling,
circumoral edema, throat tightness, and dyspnea) have been reported.



Warnings and Precautions: QT Interval Prolongation

 * NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in
   patients with known QT prolongation or in combination with other drugs known
   to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3
   antiarrhythmics, certain antipsychotics or antibiotics).

 * NUPLAZID should also be avoided in patients with a history of cardiac
   arrhythmias, as well as other circumstances that may increase the risk of the
   occurrence of torsade de pointes and/or sudden death, including symptomatic
   bradycardia, hypokalemia or hypomagnesemia, and presence of congenital
   prolongation of the QT interval.

Drug Interactions:

 * Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure.
   Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.

 * Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID
   exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with
   NUPLAZID.


See the full safety profile


Acadia Connect® helps ensure that it’s easy for your patients or residents to
start and continue taking NUPLAZID.


Enroll your patients or residents today



IMPORTANT SAFETY INFORMATION and INDICATION


See more


WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

 * Elderly patients with dementia-related psychosis treated with antipsychotic
   drugs are at an increased risk of death.
 * NUPLAZID is not approved for the treatment of patients with dementia who
   experience psychosis unless their hallucinations and delusions are related to
   Parkinson’s disease.


 * Contraindication: NUPLAZID is contraindicated in patients with a history of a
   hypersensitivity reaction to pimavanserin or any of its components. Rash,
   urticaria, and reactions consistent with angioedema (e.g., tongue swelling,
   circumoral edema, throat tightness, and dyspnea) have been reported.

 * Warnings and Precautions: QT Interval Prolongation
   
   * NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in
     patients with known QT prolongation or in combination with other drugs
     known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3
     antiarrhythmics, certain antipsychotics or antibiotics).
   
   * NUPLAZID should also be avoided in patients with a history of cardiac
     arrhythmias, as well as other circumstances that may increase the risk of
     the occurrence of torsade de pointes and/or sudden death, including
     symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of
     congenital prolongation of the QT interval.

 * Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than
   placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional
   state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait
   disturbance (2% vs <1%).
   
   

 * Drug Interactions:
   
   * Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure.
     Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
   
   * Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID
     exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with
     NUPLAZID.

Indication NUPLAZID is indicated for the treatment of hallucinations and
delusions associated with Parkinson’s disease psychosis.

Dosage and Administration Recommended dose: 34 mg capsule taken orally once
daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.

About PD Psychosis

IMPORTANT SAFETY INFORMATION and INDICATION


See more


WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

 * Elderly patients with dementia-related psychosis treated with antipsychotic
   drugs are at an increased risk of death.
 * NUPLAZID is not approved for the treatment of patients with dementia who
   experience psychosis unless their hallucinations and delusions are related to
   Parkinson’s disease.


 * Contraindication: NUPLAZID is contraindicated in patients with a history of a
   hypersensitivity reaction to pimavanserin or any of its components. Rash,
   urticaria, and reactions consistent with angioedema (e.g., tongue swelling,
   circumoral edema, throat tightness, and dyspnea) have been reported.

 * Warnings and Precautions: QT Interval Prolongation
   
   * NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in
     patients with known QT prolongation or in combination with other drugs
     known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3
     antiarrhythmics, certain antipsychotics or antibiotics).
   
   * NUPLAZID should also be avoided in patients with a history of cardiac
     arrhythmias, as well as other circumstances that may increase the risk of
     the occurrence of torsade de pointes and/or sudden death, including
     symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of
     congenital prolongation of the QT interval.

 * Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than
   placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional
   state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait
   disturbance (2% vs <1%).
   
   

 * Drug Interactions:
   
   * Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure.
     Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
   
   * Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID
     exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with
     NUPLAZID.

Indication NUPLAZID is indicated for the treatment of hallucinations and
delusions associated with Parkinson’s disease psychosis.

Dosage and Administration Recommended dose: 34 mg capsule taken orally once
daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.

Search Assistant Manager




Hi, How can I help you?


REFERENCES:

 1. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of
    “benign hallucinations” in Parkinson disease. Arch Neurol.
    2006;63(5):713-716.
 2. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of
    nonmotor symptoms of Parkinson’s disease to health care professionals: an
    international study using the nonmotor symptoms questionnaire. Mov Disord.
    2010;25(6):704-709.
 3. Acadia Pharmaceuticals Inc. NUPLAZID® [package insert]. San Diego, CA; 2023.
 4. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with
    Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3
    trial. Lancet. 2014;383(9916):533-540.
 5. Acadia Pharmaceuticals Inc. NUPLAZID Advisory Committee Briefing Document.
    San Diego, CA: Sponsor Background Information for a Meeting of the
    Psychopharmacologic Drugs Advisory Committee. March 29, 2016.

×

You are now leaving NuplazidHCP.com to visit a website that is not owned or
operated by Acadia Pharmaceuticals Inc. Links to all outside sites are provided
as resources only. Acadia Pharmaceuticals Inc. does not accept responsibility or
liability for the content or services of other websites.


Stay
Continue

×

You are now leaving NuplazidHCP.com to visit a website that is not owned or
operated by Acadia Pharmaceuticals Inc. Links to all outside sites are provided
as resources only. Acadia Pharmaceuticals Inc. does not accept responsibility or
liability for the content or services of other websites.


Stay
Continue



This website is intended for US healthcare professionals only.


 * Contact Us
 * Privacy Policy
 * Cookie Policy
 * Terms of Use
 * Cookie Settings



©2024 Acadia Pharmaceuticals Inc. Acadia, Acadia Connect, and NUPLAZID are
registered trademarks of Acadia Pharmaceuticals Inc. All other trademarks are
the property of their respective owners. All rights reserved. NU-1872-v13 01/24.

12830 El Camino Real, Suite 400
San Diego, CA 92130

Safety & Tolerability




By clicking “Accept All Cookies”, you agree to the storing of cookies on your
device to enhance site navigation, analyze site usage, and assist in our
marketing efforts. Cookie Policy

Cookies Settings Accept All Cookies



PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.

Back Button


PERFORMANCE COOKIES



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Reject All Confirm My Choices